Investor Relations

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained-delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® (dexamethasone intraocular suspension) 9%, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

Oct 12, 2021
EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting
Sep 17, 2021
EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
Sep 07, 2021
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Aug 10, 2021
EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
Aug 04, 2021
EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Stern Investor Relations
p. 212.362.1200

Caren Begun
p. 973.263.8585